GlaxoSmithKline Capital plc, founded in 2000 and based in the United Kingdom, serves as the financing arm of GlaxoSmithKline plc. The company’s primary purpose is to facilitate the group's funding needs through the issuance and management of debt instruments. Key services include the issuance of bonds to support the parent company's pharmaceutical and consumer healthcare operations.
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
GlaxoSmithKline Capital plc began issuing bonds shortly after its establishment in 2000, with notable issuances including a £500 million bond in 2009 designed to refinance existing debt. In recent years, the company offered bonds with yields that have been competitive within the pharmaceutical industry, reflecting the strong credit quality of its parent company. The issuer's bond features include callable options, enhancing flexibility for investors. Recent news highlighted plans to issue new bonds to support ongoing research initiatives and expansion in emerging markets.